FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $34,115 | -55.5% | 16,092 | 0.0% | 0.00% | -57.1% |
Q2 2023 | $76,598 | -53.5% | 16,092 | -44.3% | 0.01% | -56.2% |
Q1 2023 | $164,587 | -43.5% | 28,875 | 0.0% | 0.02% | -46.7% |
Q4 2022 | $291,349 | -55.5% | 28,875 | -1.0% | 0.03% | -55.2% |
Q3 2022 | $654,000 | +3.0% | 29,178 | +13.8% | 0.07% | +6.3% |
Q2 2022 | $635,000 | -35.9% | 25,645 | +0.4% | 0.06% | -25.0% |
Q1 2022 | $990,000 | -33.0% | 25,545 | +1.1% | 0.08% | -29.4% |
Q4 2021 | $1,478,000 | +0.7% | 25,257 | +2.0% | 0.12% | -9.2% |
Q3 2021 | $1,467,000 | -31.7% | 24,758 | +0.1% | 0.13% | -33.8% |
Q2 2021 | $2,147,000 | +19.0% | 24,738 | +13.1% | 0.20% | +11.9% |
Q1 2021 | $1,804,000 | -10.5% | 21,878 | -1.3% | 0.18% | -17.3% |
Q4 2020 | $2,016,000 | +39.5% | 22,166 | -38.7% | 0.21% | +19.6% |
Q3 2020 | $1,445,000 | +1.7% | 36,153 | -12.7% | 0.18% | +2.9% |
Q2 2020 | $1,421,000 | +61.7% | 41,407 | +4.6% | 0.17% | +56.8% |
Q1 2020 | $879,000 | -31.2% | 39,599 | -39.3% | 0.11% | -1.8% |
Q4 2019 | $1,278,000 | – | 65,286 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |